select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Non-Alcoholic Steatohepatitis-Pipeline Review, H1 2015

Non-Alcoholic Steatohepatitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6026IDB
  • |
  • Pages: 215
  • |
  • January 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Non-Alcoholic Steatohepatitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Non-Alcoholic Steatohepatitis-Pipeline Review, H1 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Non-Alcoholic Steatohepatitis Overview 8

Therapeutics Development 9

Pipeline Products for Non-Alcoholic Steatohepatitis-Overview 9

Pipeline Products for Non-Alcoholic Steatohepatitis-Comparative Analysis 10

Non-Alcoholic Steatohepatitis-Therapeutics under Development by Companies 11

Non-Alcoholic Steatohepatitis-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Non-Alcoholic Steatohepatitis-Products under Development by Companies 17

Non-Alcoholic Steatohepatitis-Companies Involved in Therapeutics Development 21

Cardax Pharmaceuticals, Inc. 21

Conatus Pharmaceuticals Inc. 22

Connexios Life Sciences Pvt. Ltd. 23

Cubist Pharmaceuticals, Inc. 24

Daiichi Sankyo Company, Limited 25

Dr. Falk Pharma GmbH 26

Dynavax Technologies Corporation 27

Galectin Therapeutics, Inc. 28

Galmed International Ltd. 29

Genfit SA 30

Gilead Sciences, Inc. 31

Immuron Limited 32

Intercept Pharmaceuticals, Inc. 33

Isis Pharmaceuticals, Inc. 34

Jenrin Discovery, Inc. 35

Kadmon Corporation, LLC 36

Kissei Pharmaceutical Co., Ltd. 37

Kyorin Pharmaceutical Co., Ltd. 38

La Jolla Pharmaceutical Company 39

Mochida Pharmaceutical Co., Ltd. 40

Novo Nordisk A/S 41

Pharmaxis Limited 42

Phenex Pharmaceuticals AG 43

ProMetic Life Sciences Inc. 44

Raptor Pharmaceuticals Corp. 45

Shire Plc 46

Stelic Institute & Co. 47

Tobira Therapeutics, Inc. 48

Verva Pharmaceuticals Limited 49

Wellstat Therapeutics Corporation 50

Zafgen Inc. 51

Zydus Cadila Healthcare Limited 52

Non-Alcoholic Steatohepatitis-Therapeutics Assessment 53

Assessment by Monotherapy Products 53

Assessment by Target 54

Assessment by Mechanism of Action 57

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

AM-0010-Drug Profile 64

Aramchol-Drug Profile 65

CDX-085-Drug Profile 67

cenicriviroc-Drug Profile 69

CNX-014-Drug Profile 71

CNX-023-Drug Profile 72

CNX-024-Drug Profile 73

CNX-025-Drug Profile 74

cysteamine DR-Drug Profile 75

DV-1179-Drug Profile 78

emricasan-Drug Profile 80

GCS-100-Drug Profile 82

GFT-505-Drug Profile 84

GR-MD-02-Drug Profile 87

icosapent ethyl-Drug Profile 89

IMM-124E-Drug Profile 90

ISIS-DGAT2Rx-Drug Profile 92

JD-5037-Drug Profile 93

JKB-119-Drug Profile 94

JKB-121-Drug Profile 95

KD-025-Drug Profile 96

liraglutide (recombinant)-Drug Profile 98

LJPC-1010-Drug Profile 101

MAT-8800-Drug Profile 102

methazolamide-Drug Profile 103

MGL-3196-Drug Profile 104

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 106

ND-630-Drug Profile 108

ND-654-Drug Profile 109

norursodeoxycholic acid-Drug Profile 110

obeticholic acid-Drug Profile 111

PBI-4050-Drug Profile 114

PN-2XXX-Drug Profile 115

Px-102-Drug Profile 116

Px-103-Drug Profile 117

PXS-4728A-Drug Profile 118

PZ-235-Drug Profile 119

remogliflozin etabonate-Drug Profile 120

saroglitazar-Drug Profile 123

SHP-626-Drug Profile 124

simtuzumab-Drug Profile 125

Small Molecule for Non-Alcoholic Steatohepatitis-Drug Profile 127

Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis-Drug Profile 128

Small Molecules to Activate AMPK for Fatty Liver Disease-Drug Profile 129

Small Molecules to Inhibit ACC for Metabolic Disorders-Drug Profile 130

solithromycin-Drug Profile 131

STNM-09-Drug Profile 133

TGFTX-3 Program-Drug Profile 134

tipelukast-Drug Profile 135

TRX-318-Drug Profile 137

VK-0214-Drug Profile 138

VVP-100-X-Drug Profile 139

ZGN-839-Drug Profile 140

Non-Alcoholic Steatohepatitis-Recent Pipeline Updates 141

Non-Alcoholic Steatohepatitis-Dormant Projects 199

Non-Alcoholic Steatohepatitis-Discontinued Products 201

Non-Alcoholic Steatohepatitis-Product Development Milestones 202

Featured News & Press Releases 202

Appendix 210

Methodology 210

Coverage 210

Secondary Research 210

Primary Research 210

Expert Panel Validation 210

Contact Us 211

Disclaimer 211

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2015 13

Number of Products under Development for Non-Alcoholic Steatohepatitis-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Development by Companies, H1 2015 (Contd..2) 23

Products under Development by Companies, H1 2015 (Contd..3) 24

Non-Alcoholic Steatohepatitis-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 25

Non-Alcoholic Steatohepatitis-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 26

Non-Alcoholic Steatohepatitis-Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2015 27

Non-Alcoholic Steatohepatitis-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 28

Non-Alcoholic Steatohepatitis-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 29

Non-Alcoholic Steatohepatitis-Pipeline by Dr. Falk Pharma GmbH, H1 2015 30

Non-Alcoholic Steatohepatitis-Pipeline by Dynavax Technologies Corporation, H1 2015 31

Non-Alcoholic Steatohepatitis-Pipeline by Galectin Therapeutics, Inc., H1 2015 32

Non-Alcoholic Steatohepatitis-Pipeline by Galmed International Ltd., H1 2015 33

Non-Alcoholic Steatohepatitis-Pipeline by Genfit SA, H1 2015 34

Non-Alcoholic Steatohepatitis-Pipeline by Gilead Sciences, Inc., H1 2015 35

Non-Alcoholic Steatohepatitis-Pipeline by Immuron Limited, H1 2015 36

Non-Alcoholic Steatohepatitis-Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 37

Non-Alcoholic Steatohepatitis-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 38

Non-Alcoholic Steatohepatitis-Pipeline by Jenrin Discovery, Inc., H1 2015 39

Non-Alcoholic Steatohepatitis-Pipeline by Kadmon Corporation, LLC, H1 2015 40

Non-Alcoholic Steatohepatitis-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 41

Non-Alcoholic Steatohepatitis-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 42

Non-Alcoholic Steatohepatitis-Pipeline by La Jolla Pharmaceutical Company, H1 2015 43

Non-Alcoholic Steatohepatitis-Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015 44

Non-Alcoholic Steatohepatitis-Pipeline by Novo Nordisk A/S, H1 2015 45

Non-Alcoholic Steatohepatitis-Pipeline by Pharmaxis Limited, H1 2015 46

Non-Alcoholic Steatohepatitis-Pipeline by Phenex Pharmaceuticals AG, H1 2015 47

Non-Alcoholic Steatohepatitis-Pipeline by ProMetic Life Sciences Inc., H1 2015 48

Non-Alcoholic Steatohepatitis-Pipeline by Raptor Pharmaceuticals Corp., H1 2015 49

Non-Alcoholic Steatohepatitis-Pipeline by Shire Plc, H1 2015 50

Non-Alcoholic Steatohepatitis-Pipeline by Stelic Institute & Co., H1 2015 51

Non-Alcoholic Steatohepatitis-Pipeline by Tobira Therapeutics, Inc., H1 2015 52

Non-Alcoholic Steatohepatitis-Pipeline by Verva Pharmaceuticals Limited, H1 2015 53

Non-Alcoholic Steatohepatitis-Pipeline by Wellstat Therapeutics Corporation, H1 2015 54

Non-Alcoholic Steatohepatitis-Pipeline by Zafgen Inc., H1 2015 55

Non-Alcoholic Steatohepatitis-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 56

Assessment by Monotherapy Products, H1 2015 57

Number of Products by Stage and Target, H1 2015 59

Number of Products by Stage and Mechanism of Action, H1 2015 62

Number of Products by Stage and Route of Administration, H1 2015 65

Number of Products by Stage and Molecule Type, H1 2015 67

Non-Alcoholic Steatohepatitis Therapeutics-Recent Pipeline Updates, H1 2015 145

Non-Alcoholic Steatohepatitis-Dormant Projects, H1 2015 203

Non-Alcoholic Steatohepatitis-Dormant Projects (Contd..1), H1 2015 204

Non-Alcoholic Steatohepatitis-Discontinued Products, H1 2015 205

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2015 13

Number of Products under Development for Non-Alcoholic Steatohepatitis-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 57

Number of Products by Top 10 Targets, H1 2015 58

Number of Products by Stage and Top 10 Targets, H1 2015 58

Number of Products by Top 10 Mechanism of Actions, H1 2015 61

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 61

Number of Products by Top 10 Routes of Administration, H1 2015 64

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65

Number of Products by Top 10 Molecule Types, H1 2015 66

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Cardax Pharmaceuticals, Inc.

Conatus Pharmaceuticals Inc.

Connexios Life Sciences Pvt. Ltd.

Cubist Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

Dr. Falk Pharma GmbH

Dynavax Technologies Corporation

Galectin Therapeutics, Inc.

Galmed International Ltd.

Genfit SA

Gilead Sciences, Inc.

Immuron Limited

Intercept Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Jenrin Discovery, Inc.

Kadmon Corporation, LLC

Kissei Pharmaceutical Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

La Jolla Pharmaceutical Company

Mochida Pharmaceutical Co., Ltd.

Novo Nordisk A/S

Pharmaxis Limited

Phenex Pharmaceuticals AG

ProMetic Life Sciences Inc.

Raptor Pharmaceuticals Corp.

Shire Plc

Stelic Institute & Co.

Tobira Therapeutics, Inc.

Verva Pharmaceuticals Limited

Wellstat Therapeutics Corporation

Zafgen Inc.

Zydus Cadila Healthcare Limited

Non-Alcoholic Steatohepatitis Therapeutic Products under Development, Key Players in Non-Alcoholic Steatohepatitis Therapeutics, Non-Alcoholic Steatohepatitis Pipeline Overview, Non-Alcoholic Steatohepatitis Pipeline, Non-Alcoholic Steatohepatitis Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]